注:本文篇幅较长,仅作行业信息与观点分享,不构成任何投资建议。中国Biotech何时能盈利?这个问题如果置于不同时间节点,答案截然不同。将时间拉长,2015年“7·22”之后,审评体系重构,创新药进入快车道。2018年和2019年,对于创新药公司而言,是美好的开始。港股18A和A股科创板第五套先后开闸,众多未盈利的创新药公司找到了新的融资路径,纷纷选择登陆二级市场,A股和港股迎来敲钟盛宴。百济神州...
Source Link注:本文篇幅较长,仅作行业信息与观点分享,不构成任何投资建议。中国Biotech何时能盈利?这个问题如果置于不同时间节点,答案截然不同。将时间拉长,2015年“7·22”之后,审评体系重构,创新药进入快车道。2018年和2019年,对于创新药公司而言,是美好的开始。港股18A和A股科创板第五套先后开闸,众多未盈利的创新药公司找到了新的融资路径,纷纷选择登陆二级市场,A股和港股迎来敲钟盛宴。百济神州...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.